scholarly journals Disseminated cryptococcosis and fluconazole resistant oral candidiasis in a patient with acquired immunodeficiency syndrome (AIDS)

2010 ◽  
Vol 4 (10) ◽  
pp. 674-678 ◽  
Author(s):  
Rajendra J Kothavade ◽  
Chetan M Oberai ◽  
Arvind G Valand ◽  
Mehroo H Panthaki
Keyword(s):  
Oral Candidiasis ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Body Parts ◽  
Root Cause ◽  
Fluconazole Resistant ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
In Vitro Drug Susceptibility

Disseminated cryptococcosis and recurrent oral candidiasis was presented in a-heterosexual AIDS patient. Candida tropicalis (C.tropicalis) was isolated from the oral pseudomembranous plaques and Cryptococcus neoformans (C. neoformans) was isolated from maculopapular lesions on body parts (face, hands and chest) and body fluids (urine, expectorated sputum, and cerebrospinal fluid). In vitro drug susceptibility testing on the yeast isolates demonstrated resistance to fluconazole acquired by C. tropicalis which was a suggestive possible root cause of recurrent oral candidiasis in this patient.

scholarly journals New Approach for Drug Susceptibility Testing: Monitoring the Stress Response of Mycobacteria

2009 ◽  
Vol 53 (11) ◽  
pp. 4598-4603 ◽  
Author(s):  
Ronald J. Rieder ◽  
Zhihui Zhao ◽  
Boris Zavizion
Keyword(s):  
Susceptibility Testing ◽  
Physiological Stress ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Bacterial Suspension ◽  
Prolonged Incubation ◽  
New Approach ◽  
Induced Stress ◽  
In Vitro Drug Susceptibility

ABSTRACT Methods currently used for in vitro drug susceptibility testing are based on the assessment of bacterial growth-related processes. This reliance on cellular reproduction leads to prolonged incubation times, particularly for slowly growing organisms such as mycobacteria. A new rapid phenotypic method for the drug susceptibility testing of mycobacteria is described. The method is based on the detection of the physiological stress developed by susceptible mycobacterial cells in the presence of an antimicrobial compound. The induced stress was quantified by differential monitoring of the dielectric properties of the bacterial suspension, an easily measurable electronic property. The data presented here characterize the stress developed by Mycobacterium tuberculosis cells treated with rifampin (rifampicin), isoniazid, ethambutol, and pyrazinamide. Changes in the dielectric-based profiles of the drug-treated bacteria revealed the respective susceptibilities in near real time, and the susceptibilities were well correlated with conventional susceptibility test data.

Evaluation of high-throughput assays for in vitro drug susceptibility testing of Tritrichomonas foetus trophozoites

2016 ◽  
Vol 223 ◽  
pp. 34-37 ◽  
Author(s):  
Chris Bader ◽  
Jeba Jesudoss Chelladurai ◽  
Kylie Thompson ◽  
Cindy Hall ◽  
Steve A. Carlson ◽  
...  
Keyword(s):  
High Throughput ◽  
Susceptibility Testing ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Tritrichomonas Foetus ◽  
In Vitro Drug Susceptibility

scholarly journals Comparative Evaluation of FUNGITEST and Broth Microdilution Methods for Antifungal Drug Susceptibility Testing of Candida Species and Cryptococcus neoformans

1998 ◽  
Vol 36 (4) ◽  
pp. 926-930 ◽  
Author(s):  
Kate G. Davey ◽  
Ann D. Holmes ◽  
Elizabeth M. Johnson ◽  
Adrien Szekely ◽  
David W. Warnock
Keyword(s):  
Cryptococcus Neoformans ◽  
Amphotericin B ◽  
Susceptibility Testing ◽  
Clinical Laboratory ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
National Committee ◽  
Broth Microdilution ◽  
Fluconazole Resistant

The FUNGITEST method (Sanofi Diagnostics Pasteur, Paris, France) is a microplate-based procedure for the breakpoint testing of six antifungal agents (amphotericin B, flucytosine, fluconazole, itraconazole, ketoconazole, and miconazole). We compared the FUNGITEST method with a broth microdilution test, performed according to National Committee for Clinical Laboratory Standards document M27-A guidelines, for determining the in vitro susceptibilities of 180 isolates ofCandida spp. (50 C. albicans, 50C. glabrata, 10 C. kefyr, 20C. krusei, 10 C. lusitaniae, 20C. parapsilosis, and 20 C. tropicalisisolates) and 20 isolates of Cryptococcus neoformans. Overall, there was 100% agreement between the methods for amphotericin B, 95% agreement for flucytosine, 84% agreement for miconazole, 83% agreement for itraconazole, 77% agreement for ketoconazole, and 76% agreement for fluconazole. The overall agreement between the methods exceeded 80% for all species tested with the exception ofC. glabrata (71% agreement). The poorest agreement between the results for individual agents was seen with C. glabrata (38% for fluconazole, 44% for ketoconazole, and 56% for itraconazole) and C. tropicalis (50% for miconazole). The FUNGITEST method misclassified as susceptible 2 of 12 (16.6%) fluconazole-resistant isolates, 2 of 10 (20%) itraconazole-resistant isolates, and 4 of 8 (50%) ketoconazole-resistant isolates of several Candida spp. Further development of the FUNGITEST procedure will be required before it can be recommended as an alternative method for the susceptibility testing of Candida spp. or C. neoformans.

scholarly journals Recurrent candidaemia in a neonate with Hirschsprung's disease: fluconazole resistance and genetic relatedness of eight Candida tropicalis isolates

2006 ◽  
Vol 55 (4) ◽  
pp. 423-428 ◽  
Author(s):  
Pei Pei Chong ◽  
David Ching-Soo Chieng ◽  
Lee Yean Low ◽  
Asma Hafeez ◽  
Mariana Nor Shamsudin ◽  
...  
Keyword(s):  
Candida Tropicalis ◽  
Hirschsprung's Disease ◽  
Hirschsprung’S Disease ◽  
Genetic Relatedness ◽  
Infectious Agent ◽  
Venous Catheter ◽  
Drug Susceptibility ◽  
Fluconazole Resistant ◽  
Susceptibility Tests

The incidence of candidaemia among immunocompromised patients in Malaysia is increasing at an alarming rate. Isolation of clinical strains that are resistant to fluconazole has also risen markedly. We report here the repeated isolation of Candida tropicalis from the blood of a neonatal patient with Hirschsprung's disease. In vitro fluconazole susceptibility tests of the eight isolates obtained at different time points showed that seven of the isolates were resistant and one isolate was scored as susceptible dose-dependent. Random amplification of polymorphic DNA fingerprinting of the isolates using three primers and subsequent phylogenetic analysis revealed that these isolates were highly similar strains having minor genetic divergence, with a mean pairwise similarity coefficient of 0·893±0·041. The source of the infectious agent was thought to be the central venous catheter, as culture of its tip produced fluconazole-resistant C. tropicalis. This study demonstrates the utility of applying molecular epidemiology techniques to complement traditional mycological culture and drug susceptibility tests for accurate and appropriate management of recurrent candidaemia and highlights the need for newer antifungals that can combat the emergence of fluconazole-resistant C. tropicalis strains.

Growth, Drug Susceptibility, and Gene Expression Profiling of Plasmodium falciparum Cultured in Medium Supplemented with Human Serum

2007 ◽  
Vol 12 (8) ◽  
pp. 1109-1114 ◽  
Author(s):  
Kshipra Singh ◽  
Ameeta Agarwal ◽  
Shabana I. Khan ◽  
Larry A. Walker ◽  
Babu L. Tekwani
Keyword(s):  
Gene Expression ◽  
Plasmodium Falciparum ◽  
Human Serum ◽  
Global Gene Expression ◽  
Drug Susceptibility ◽  
Growth Cycle ◽  
In Vitro Cultivation ◽  
Human Malaria Parasite ◽  
In Vitro Drug Susceptibility

In vitro cultivation of Plasmodium falciparum has been extremely useful in understanding the biology of the human malaria parasite as well as research on the discovery of new antimalarial drugs and vaccines. A chemically defined serum-free medium supplemented with lipid-rich bovine serum albumin (AlbuMAX I) offers the following advantages over human serum-supplemented media for the in vitro culture of P. falciparum: 1) improved growth profile, with more than a 2-fold higher yield of the parasites at any stage of the growth cycle; 2) suitability for in vitro antimalarial screening, as the parasites grown in AlbuMAX and human serum-supplemented media show similar sensitivity to standard and novel antimalarials as well as natural product extracts in the in vitro drug susceptibility assays; and 3) DNA microarray analysis comparing the global gene expression profile of sorbitol-synchronized P. falciparum trophozoites grown in the 2 different media, indicating minimal differences. ( Journal of Biomolecular Screening 2007:1109-1114)

scholarly journals In VivoandIn VitroEfficacy of Chloroquine againstPlasmodium malariaeandP. ovalein Papua, Indonesia

2010 ◽  
Vol 55 (1) ◽  
pp. 197-202 ◽  
Author(s):  
H. Siswantoro ◽  
B. Russell ◽  
A. Ratcliff ◽  
B. Prasetyorini ◽  
F. Chalfein ◽  
...  
Keyword(s):  
Parasite Clearance ◽  
Plasmodium Malariae ◽  
Drug Susceptibility ◽  
Drug Susceptibility Testing ◽  
Chloroquine Resistance ◽  
Ring Stage ◽  
Trophozoite Stage ◽  
Nm Range

ABSTRACTReports of potential drug-resistant strains ofPlasmodium malariaein western Indonesia raise concerns that chloroquine resistance may be emerging inP. malariaeandP. ovale. In order to assess this,in vivoandin vitroefficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due toP. ovaleorP. malariaewere enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients withP. malariaeorP. ovaleparasitemia greater than 1,000 per microliter underwentin vitroantimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae,n= 46;P. ovale,n= 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) forP. malariaeand 150 (95% CI, 54 to 245) forP. ovale(P= 0.18). One patient infected withP. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4.In vitrodrug susceptibility assays were carried out successfully for 40 isolates (34 infected withP. malariaeand 6 withP. ovale). TheP. malariaeinfections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC50s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0];P= 0.01). The EC50for chloroquine inP. ovalewas also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy againstP. ovaleandP. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times.

scholarly journals Different effect of benzylacyclouridine on the toxic and therapeutic effects of azidothymidine in mice

Blood ◽  
1990 ◽  
Vol 76 (11) ◽  
pp. 2216-2221 ◽  
Author(s):  
A Falcone ◽  
JW Darnowski ◽  
RM Ruprecht ◽  
SH Chu ◽  
I Brunetti ◽  
...  
Keyword(s):  
Leukemia Virus ◽  
Hematologic Toxicity ◽  
Therapeutic Effects ◽  
Dependent Manner ◽  
Aids Related Complex ◽  
Effective Doses ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Oral Doses

Abstract It has been reported that in vitro uridine (Urd) can reverse azidothymidine (AZT) cytotoxicity without decreasing anti-human immunodeficiency virus (HIV) activity. Our studies in mice have shown that daily oral doses of benzylacyclouridine (BAU), an inhibitor of Urd breakdown, also reduces AZT hematologic toxicity, presumably by elevating the plasma concentration of Urd. We now extend these murine studies and report the effect of various doses of exogenous Urd, various doses of BAU, or the combination of BAU and Urd, administered daily, on AZT-induced toxicity. In mice receiving concomitant AZT, daily doses of Urd of 1,000 to 2,000 mg/kg increase peripheral reticulocytes and slightly reduce AZT-induced hematologic toxicity. However, the range of effective doses is narrow, and higher doses of Urd (greater than 3,000 mg/kg/d) significantly enhance hematologic toxicity. At its most effective dose, (2,000 mg/kg/d), Urd produces 28% mortality. In contrast, BAU doses up to 300 mg/kg/d reduced AZT-related hematologic toxicity in a dose-dependent manner without mortality. Higher daily doses of BAU and the combination of BAU with low doses of Urd were not more effective. Studies conducted in mice infected with the Rauscher murine leukemia virus (RLV) indicate that BAU does not impair the antiretroviral effect of AZT when administered at doses that reduce AZT-induced anemia and leukopenia. These findings may be significant for the treatment of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex.

Sign in / Sign up

Export Citation Format

Share Document